Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 6, 2012, Pages 627-634

  Nielsen, Patricia Switten ^a   Riber Hansen, Rikke ^a   Raundahl, Jakob ^b,c   Steiniche, Torben ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Visiopharm A/S   (Denmark)

^c Rungsted High School   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; MELAN A;

ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; METABOLISM; NEVUS; SKIN TUMOR;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MART-1 ANTIGEN; MELANOCYTES; MELANOMA; NEVUS; SKIN NEOPLASMS;

EID: 84864227700     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0360-OA     Document Type: Article

References (30)

1. Scholzen T, Gerdes J. The ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-322. (Pubitemid 30054364)
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
3. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003; 36(3):131-149. (Pubitemid 36808270)
4. Nielsen PS, Riber-Hansen R, Steiniche T. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol. 2011;33(4):361-370.
5. Taheri ZM, Mehrafza M, Mohammadi F, Khoddami M, Bahadori M, Masjedi MR. The diagnostic value of ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2008; 132(4):694-697. (Pubitemid 351489624)
6. Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 2005;29(3):295-304. (Pubitemid 40321964)
7. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130(10):1448-1453.
8. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57(7):675-681. (Pubitemid 38901478)
9. Grala B, Markiewicz T, Kozlowski W, Osowski S, Slodkowska J, Papierz W. New automated image analysis method for the assessment of ki-67 labeling index in meningiomas. Folia Histochem Cytobiol. 2009;47(4):587-592.
10. Rudolph P, Schubert C, Schubert B, Parwaresch R. Proliferation marker ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol. 1997; 37(2, pt 1):169-178. (Pubitemid 27355700)
11. Ivan D, Prieto VG. Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls. Future Oncol. 2010;6(7):1163-1175.
12. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. p53-protein and ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology. 1997;30(1):57-63. (Pubitemid 27072449)
13. Henrique R, Azevedo R, Bento MJ, Domingues JC, Silva C, Jeronimo C. Prognostic value of ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol. 2000;43(6):991-1000.
14. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochem-ical characteristics of melanoma. J Cutan Pathol. 2008;35(5):433-444.
15. Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol. 2001; 44(2):188-192. (Pubitemid 32172178)
16. Puri PK, Valdes CL, Burchette JL, Grichnik JM, Turner JW, Selim MA. Accurate identification of proliferative index in melanocytic neoplasms with melan-A/Ki-67 double stain. J Cutan Pathol. 2010;37(9):1010-1012.
17. Lebe B, Pabuccuoglu U, Ozer E. The significance of ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007;15(2): 160-164. (Pubitemid 46828222)
18. Lejeune M, Jaen J, Pons L, et al. Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure. J Anat. 2008;212(6):868-878. (Pubitemid 351772667)
19. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and ki-67. Breast Cancer Res. 2010;12(4):R56.
20. Gonzalez RC, Woods RE. Digital Image Processing. Upper Saddle River, NJ: Pearson Education Inc; 2008:738-763.
21. Grunkin M. Working With Visiomorph. Hoersholm, Denmark: Visiopharm A/S; 2008.
22. Grunkin M, Raundahl J, Foged NT. Practical considerations of image analysis and quantification of signal transduction IHC staining. Methods Mol Biol. 2011;717:143-154.
23. Gundersen HJ, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988;96(5):379-394.
24. Altman DG. Statistics With Confidence: Confidence Intervals and Statistical Guidelines. London, England: BMJ Books; 2000.
25. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857-872. (Pubitemid 28185165)
26. Tihan T, Davis R, Elowitz E, DiCostanzo D, Moll U. Practical value of ki-67 and p53 labeling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas. Arch Pathol Lab Med. 2000;124(1):108-113. (Pubitemid 30053782)
27. Grzybicki DM, Liu Y, Moore SA, et al. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer. 2001;92(10):2720- 2726. (Pubitemid 33049457)
28. Hsu CY, Ho DM, Yang CF, Chiang H. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol. 2003;16(9):951-957. (Pubitemid 37152026)
29. Gilles FH, Tavare CJ, Becker LE, et al. Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study. Pediatr Dev Pathol. 2008;11(2):108-117.
30. Walker RA. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49(4):406-410. (Pubitemid 44401548)